(Q67688877)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1709026%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

title

5-aza-2'-deoxycytidine in advanced or recurrent cancer of the uterine cervix (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1709026%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

5-aza-2′-deoxycytidine in advanced or recurrent cancer of the uterine cervix (English)

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90493-W

4 November 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90493-W

4 November 2022

author name string

J. B. Vermorken

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1709026

4 November 2022

S. Tumolo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1709026

4 November 2022

K. J. Roozendaal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1709026

4 November 2022

J. P. Guastalla

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1709026

4 November 2022

T. A. Splinter

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1709026

4 November 2022

J. Renard

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1709026

4 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1709026

4 November 2022

publication date

1 January 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1709026%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

17 September 2019

https://api.elsevier.com/content/article/PII:027753799190493W?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90493-W

https://api.elsevier.com/content/article/PII:027753799190493W?httpAccept=text/plain

4 November 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90493-W

European Journal of Cancer

4 November 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1709026%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1709026%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1709026%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

page(s)

216-217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1709026%20AND%20SRC:MED&resulttype=core&format=json

Growth inhibitory effects of 5-aza-2'-deoxycytidine in HL-60 promyelocytic leukemia cells resistant to differentiation induction.

17 September 2019

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90493-W

The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas

4 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90493-W

4 November 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1709026%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

1 reference